<p><strong>來自 ALOHA 計劃和 NU-GEN™細胞更新精華的數據顯示有助於推動實踐成功</strong></p>
<p>紐約，2026 年 5 月 15 日（GLOBE NEWSWIRE）——Obagi Medical 是一家領先的醫生分銷護膚和美學解決方案的創新公司，隸屬於 Waldencast plc（納斯達克：WALD），今天宣佈在 5 月 13 日至 17 日在田納西州納什維爾舉行的音樂城 SCALE 會議上分享的新數據。</p>
<ul>
<li>一項為期 12 周的開放標籤研究結果，評估 Obagi NU-GEN 細胞更新精華對皺紋、色素沉着、光澤、質地、緊緻度、飽滿度和感知皮膚年齡的療效和耐受性：ePoster Dr. Todd Schlessinger, MD</li>
<li>一項大規模多位醫生的真實世界評估的中期結果，評估一種新型透明質酸皮膚填充劑與醫用級護膚品結合使用的效果：ePoster Dr. Carolyn Jacob, MD</li>
</ul>
<p>“作為 FDA 註冊項目中 Obagi 填充劑的關鍵臨牀站點之一，我對 Obagi Saypha® MagIQ™的真實世界評估感到非常感興趣，” Dr. Carolyn Jacob, MD 表示。“審查來自 300 多個參與站點的結果驗證了核心臨牀結果，並明確表明 MagIQ 在大多數實踐中都有其位置。”</p>
<p>真實世界數據評估了 ALOHA（與 Obagi 透明質酸的美學領導力）計劃的中期審查，這是一個旨在通過實踐主導的洞察加速美學創新的結構化臨牀合作計劃。Obagi 預計 ALOHA 計劃將成為新的可注射填充劑的最大真實世界評估計劃。中期數據突顯出 94% 的注射者認為 Obagi Saypha® MagIQ™補充了他們當前的填充劑選擇，並顯示 43% 的患者也在評估 Obagi 護膚品。</p>
<p>“這些數據點代表了我們最新 Obagi 創新的臨牀和真實世界結果，” 美國專業渠道總經理 Drew Fine 表示。“Obagi Saypha® MagIQ™和 NU-GEN™細胞更新精華代表了支持實踐成功的重要進展，並突顯了關注 Obagi 可注射和護膚解決方案的好處。”</p>
<p>該 ePoster 代表了 NU-GEN 臨牀項目的首次數據分享。該配方經過臨牀驗證，能夠通過幫助補充 NAD+ 並同時解決九種皮膚老化跡象，顯著逆轉皮膚年齡達六年 1。</p>
<p><strong>關於 Obagi Medical</strong></p>
<p>Obagi Medical 是一家行業領先的先進護膚品牌，根植於研究和皮膚生物學，擁有超過 35 年的經驗。最初以其在 Obagi Nu-Derm®系統中治療色素沉着的領導地位而聞名，Obagi Medical 產品旨在解決多種皮膚問題，包括早衰、光損傷、皮膚色素沉着、痤瘡和陽光損傷。作為 2024 年美國增長最快的專業護膚品牌，Obagi Medical 使個人能夠實現健康、美麗的肌膚。有關 Obagi Medical 的更多信息，請訪問品牌網站，<strong>https://www.obagi.com</strong>。</p>
<p><strong>關於 Waldencast plc</strong></p>
<p>Waldencast 由 Michel Brousset 和 Hind Sebti 創立，其雄心是通過開發、收購、加速和擴展有意識的、高增長的目標驅動品牌，建立全球一流的美容和健康運營平台。Waldencast 的願景根本上基於其品牌主導的商業模式，確保與客户的緊密聯繫、業務靈活性和市場響應能力，同時保持每個品牌的獨特 DNA。實現其願景的第一步是商業合併。作為 Waldencast 平台的一部分，其品牌將受益於多品牌平台的運營規模；在大規模管理全球美容品牌方面的專業知識；平衡的投資組合以減輕類別波動；輕資產效率；以及創業獨立品牌的市場響應能力和速度。有關更多信息，請訪問：<strong>https://ir.waldencast.com</strong>。</p>
<p><strong>媒體聯繫：</strong></p>
<p>obagi@behrmancesa.com</p>
<p>1 結果基於 2025 年為期 12 周的衰老臨牀測試。個體結果可能有所不同。數據存檔於 Obagi Cosmeceuticals LLC。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1EWTNOQ00zTmpBME5UQTNJekl5TWpVek5EWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1EWTNOQ00zTmpBME5UQTNJekl5TWpVek5EWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGVlNWU4MjYtYzMzMS00MGQxLThmMDYtYjhkYmIxMjZmODMzLTEyMzY4OTktMjAyNi0wNS0xNS1lbg==/tiny/Waldencast-plc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGVlNWU4MjYtYzMzMS00MGQxLThmMDYtYjhkYmIxMjZmODMzLTEyMzY4OTktMjAyNi0wNS0xNS1lbg==/tiny/Waldencast-plc-.png"/></p>

WALD

<p>Obagi Medical 在音樂城 SCALE 會議上展示了新數據，展示其 NU-GEN 細胞更新精華和 Obagi Saypha® MagIQ™ 皮膚填充劑的有效性。ALOHA 計劃的中期結果顯示，94% 的注射醫生認為 MagIQ™ 補充了他們當前的產品，43% 的患者也考慮使用 Obagi 護膚品。NU-GEN 精華在臨牀上證明能夠減少可見的衰老跡象。Obagi Medical 旨在通過創新的護膚解決方案提升實踐成功率</p>

<p><strong>Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success</strong></p>
<div class="lb-trans"><p><strong>來自 ALOHA 計劃和 NU-GEN™細胞更新精華的數據顯示有助於推動實踐成功</strong></p>
</div><p>NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the Music City SCALE meeting taking place May 13-17 in Nashville, TN.</p>
<div class="lb-trans"><p>紐約，2026 年 5 月 15 日（GLOBE NEWSWIRE）——Obagi Medical 是一家領先的醫生分銷護膚和美學解決方案的創新公司，隸屬於 Waldencast plc（納斯達克：WALD），今天宣佈在 5 月 13 日至 17 日在田納西州納什維爾舉行的音樂城 SCALE 會議上分享的新數據。</p>
</div><ul>
<li>Results from a 12-Week Open-Label Study Evaluating the Efficacy and Tolerability of Obagi NU-GEN Cellular Renewal Serum on Wrinkles, Hyperpigmentation, Radiance, Texture, Firmness, Plumpness, and Perceived Skin Age: ePoster Dr. Todd Schlessinger, MD</li>
<li>Interim Results from a large scale Multiple Practitioner Real-World Evaluation of a Novel Hyaluronic Acid Dermal Filler in Conjunction with Medical Grade Skin Care: ePoster Dr. Carolyn Jacob, MD</li>
</ul>
<div class="lb-trans"><ul>
<li>一項為期 12 周的開放標籤研究結果，評估 Obagi NU-GEN 細胞更新精華對皺紋、色素沉着、光澤、質地、緊緻度、飽滿度和感知皮膚年齡的療效和耐受性：ePoster Dr. Todd Schlessinger, MD</li>
<li>一項大規模多位醫生的真實世界評估的中期結果，評估一種新型透明質酸皮膚填充劑與醫用級護膚品結合使用的效果：ePoster Dr. Carolyn Jacob, MD</li>
</ul>
</div><p>“As one of the pivotal clinical sites for the FDA registration programs for the Obagi fillers, I was intrigued to do a real-world evaluation of Obagi Saypha® MagIQ™,” said Dr. Carolyn Jacob, MD. “Reviewing the results from over 300 participating sites validated the core clinical results and makes it clear that there is a place for MagIQ in most practices.”</p>
<div class="lb-trans"><p>“作為 FDA 註冊項目中 Obagi 填充劑的關鍵臨牀站點之一，我對 Obagi Saypha® MagIQ™的真實世界評估感到非常感興趣，” Dr. Carolyn Jacob, MD 表示。“審查來自 300 多個參與站點的結果驗證了核心臨牀結果，並明確表明 MagIQ 在大多數實踐中都有其位置。”</p>
</div><p>The real-world data evaluated an interim review of the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program, a structured clinical collaboration program designed to accelerate aesthetic innovation through practice-led insight. Obagi anticipates that the ALOHA program will become the largest real-world evaluation program for a new injectable filler. The interim data highlights that 94% of injectors believe Obagi Saypha® MagIQ™ compliments their current filler options and shows 43% of patients also evaluating Obagi skincare.</p>
<div class="lb-trans"><p>真實世界數據評估了 ALOHA（與 Obagi 透明質酸的美學領導力）計劃的中期審查，這是一個旨在通過實踐主導的洞察加速美學創新的結構化臨牀合作計劃。Obagi 預計 ALOHA 計劃將成為新的可注射填充劑的最大真實世界評估計劃。中期數據突顯出 94% 的注射者認為 Obagi Saypha® MagIQ™補充了他們當前的填充劑選擇，並顯示 43% 的患者也在評估 Obagi 護膚品。</p>
</div><p>“These data points represent clinical and real-world results from our newest Obagi innovations,” stated Drew Fine, U.S. General Manager, Professional Channel. “Obagi Saypha® MagIQ™ and NU-GEN™ Cellular Renewal Serum represent meaningful advances that support practice success and highlight the benefits of looking at Obagi injectable and skincare solutions.”</p>
<div class="lb-trans"><p>“這些數據點代表了我們最新 Obagi 創新的臨牀和真實世界結果，” 美國專業渠道總經理 Drew Fine 表示。“Obagi Saypha® MagIQ™和 NU-GEN™細胞更新精華代表了支持實踐成功的重要進展，並突顯了關注 Obagi 可注射和護膚解決方案的好處。”</p>
</div><p>The ePoster represents the first data sharing from the NU-GEN clinical program. The formula is clinically proven to visibly rewind skin’s age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously.</p>
<div class="lb-trans"><p>該 ePoster 代表了 NU-GEN 臨牀項目的首次數據分享。該配方經過臨牀驗證，能夠通過幫助補充 NAD+ 並同時解決九種皮膚老化跡象，顯著逆轉皮膚年齡達六年 1。</p>
</div><p><strong>About Obagi Medical</strong></p>
<div class="lb-trans"><p><strong>關於 Obagi Medical</strong></p>
</div><p>Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024, Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, <strong>https://www.obagi.com</strong>.</p>
<div class="lb-trans"><p>Obagi Medical 是一家行業領先的先進護膚品牌，根植於研究和皮膚生物學，擁有超過 35 年的經驗。最初以其在 Obagi Nu-Derm®系統中治療色素沉着的領導地位而聞名，Obagi Medical 產品旨在解決多種皮膚問題，包括早衰、光損傷、皮膚色素沉着、痤瘡和陽光損傷。作為 2024 年美國增長最快的專業護膚品牌，Obagi Medical 使個人能夠實現健康、美麗的肌膚。有關 Obagi Medical 的更多信息，請訪問品牌網站，<strong>https://www.obagi.com</strong>。</p>
</div><p><strong>About Waldencast plc</strong></p>
<div class="lb-trans"><p><strong>關於 Waldencast plc</strong></p>
</div><p>Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: <strong>https://ir.waldencast.com</strong>.</p>
<div class="lb-trans"><p>Waldencast 由 Michel Brousset 和 Hind Sebti 創立，其雄心是通過開發、收購、加速和擴展有意識的、高增長的目標驅動品牌，建立全球一流的美容和健康運營平台。Waldencast 的願景根本上基於其品牌主導的商業模式，確保與客户的緊密聯繫、業務靈活性和市場響應能力，同時保持每個品牌的獨特 DNA。實現其願景的第一步是商業合併。作為 Waldencast 平台的一部分，其品牌將受益於多品牌平台的運營規模；在大規模管理全球美容品牌方面的專業知識；平衡的投資組合以減輕類別波動；輕資產效率；以及創業獨立品牌的市場響應能力和速度。有關更多信息，請訪問：<strong>https://ir.waldencast.com</strong>。</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫：</strong></p>
</div><p>obagi@behrmancesa.com</p>
<div class="lb-trans"><p>obagi@behrmancesa.com</p>
</div><p>1 Results based on a 2025 12-week aging clinical test. Individual results may vary. Data on file at Obagi Cosmeceuticals LLC.</p>
<div class="lb-trans"><p>1 結果基於 2025 年為期 12 周的衰老臨牀測試。個體結果可能有所不同。數據存檔於 Obagi Cosmeceuticals LLC。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1EWTNOQ00zTmpBME5UQTNJekl5TWpVek5EWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMDY3NCM3NjA0NTA3IzIyMjUzNDY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGVlNWU4MjYtYzMzMS00MGQxLThmMDYtYjhkYmIxMjZmODMzLTEyMzY4OTktMjAyNi0wNS0xNS1lbg==/tiny/Waldencast-plc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGVlNWU4MjYtYzMzMS00MGQxLThmMDYtYjhkYmIxMjZmODMzLTEyMzY4OTktMjAyNi0wNS0xNS1lbg==/tiny/Waldencast-plc-.png"/></p>

Obagi Medical 在音樂之城美容進步與激光教育研討會（SCALE）會議上分享了關於近期創新的新數據 | WALD 股票新聞